ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Synovitis"

  • Abstract Number: 0019 • ACR Convergence 2022

    Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age

    Meaghan Holub1, Amanda Wahhab2, Joseph Rouse2, Brandon Jutras3, Klemen Strle4, Adam Edelstein5 and Robert Lochhead6, 1Central Michigan University College of Medicine, Mount Pleasant, MI, 2Medical College of Wisconsin, Milwaukee, WI, 3Virginia Tech, Blacksburg, VA, 4Wadsworth Center, Albany, NY, 5Northwestern Medicine, Chicago, IL, 6Medical College of Wisconsin, Germantown, WI

    Background/Purpose: Peptidoglycan (PG) is a bacterial cell wall component that is known to induce innate immune responses. PG has been identified as a driver of…
  • Abstract Number: 1969 • ACR Convergence 2022

    The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis

    Silvia Piantoni1, Fabrizio Angeli1, Francesca Regola2, Franco Franceschini2 and Paolo Airò3, 1Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy

    Background/Purpose: The finding of circulating biomarkers in the field of chronic arthritis is still an unmet need, especially for the subgroup of seronegative arthritis [e.g.,…
  • Abstract Number: 0261 • ACR Convergence 2022

    Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans

    Richard Bell1, Matthew Brendel2, Justin Xiang3, AMP RA/SLE Consortium1, Edward DiCarlo1, Jennifer Anolik4, Laura Donlin1, Dana Orange5, Edward Schwarz4, Lionel Ivashkiv1 and Fei Wang2, 1Hospital for Special Surgery, New York, NY, 2Weil Cornell Medical College, New York, NY, 3Horace Grant High School, New York, NY, 4University of Rochester Medical Center, Rochester, NY, 5The Rockefeller University, New York, NY

    Background/Purpose: Synovial pathotyping is a critical step in understanding the etiology of inflammatory arthritis as different pathotypes have differential response to therapy. Determining these pathotypes…
  • Abstract Number: 1971 • ACR Convergence 2022

    Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment

    Sascha Heckert1, Sytske Anne Bergstra2, Yvonne Goekoop-Ruiterman3, Melek Guler-Yuksel4, Willem Lems5, Xanthe Matthijssen6, Maikel Van Oosterhout7, Tom Huizinga6 and CF Allaart6, 1Leiden University Medical Centre, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3HagaZiekenhuis, The Hague, Netherlands, 4Maasstad ziekenhuis, Rotterdam, Netherlands, 5Amsterdam University Medical Centers, Amsterdam, Netherlands, 6Leiden University Medical Center, Leiden, Netherlands, 7Groene Hart Ziekenhuis, Gouda, Netherlands

    Background/Purpose: In Rheumatoid Arthritis (RA), both systemic and local disease activity have been shown to be associated with joint damage progression. Earlier we showed that…
  • Abstract Number: 0404 • ACR Convergence 2022

    Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial

    Raphael Micheroli1, Tim Killeen2, Hyejin Jo3, Kenneth Kwok3, Bassel Elzorkany4, Caroline Ospelt5, Adrian Ciurea6 and Michael Nissen7, 1University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, 2Pfizer Ltd, Tadworth, Switzerland, 3Pfizer Inc, New York, NY, 4Department of Rheumatology, Cairo University, Cairo, Egypt, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 6University Hospital Zurich, Zürich, Switzerland, 7Hopitaux Universitaires de Genève, Geneva, Switzerland

    Background/Purpose: Sites of peripheral joint and enthesitis involvement in AS vary. Tofacitinib is an oral Janus kinase inhibitor for the treatment of AS. Differential site-specific…
  • Abstract Number: 1979 • ACR Convergence 2022

    Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients

    Costantino Pitzalis1, rebecca hands2, Swamy Venuturupalli3, Ami Ben-artzi4, Eric Ruderman5, Harris Perlman6, Arthur Mandelin5, Mara Leach7, Addison Hasselbach7, Bonnie Abbruzzese7, Rachael Hershey7, Beth Potter7, Jessica Fitzpatrick7, Aaron Thornton7, Michael Blue7, Jonathan Graf8, David Ralph7 and Michael Rosol7, 1Queen Mary University of London, London, United Kingdom, 2William Harvey Research Institute, London, United Kingdom, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4Ami Ben-Artzi, MD Inc., Beverly Hills, CA, 5Northwestern University Feinberg School of Medicine, Chicago, IL, 6Northwestern University, Chicago, IL, 7Navidea Biopharmaceuticals, Dublin, OH, 8Ucsf, San Francisco, CA

    Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
  • Abstract Number: 0500 • ACR Convergence 2022

    T Cell and Macrophage Synergy Drive Inflammatory Synovial Fibroblasts in Rheumatoid but Not Psoriatic Arthritis

    Achilleas Floudas1, conor Smith2, Orla Tynan3, Nuno Neto4, Krishna Vinod5, Sarah Wade6, Megan Hanlon7, Clare Cunningham4, Viviana Marzaioli8, Mary Canavan9, Jean Fletcher3, Ronan Mullan10, Suzanne Cole11, Ling-Yang Hao12, Michael Monaghan4, Sunil Nagpal13, Douglas Veale14 and Ursula Fearon4, 1Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, 2bTrinity College Dublin, Dublin, Ireland, 3Trinity Biomedical Sciences Institute, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5Janssen, Spring House, PA, 6Trinity Biomedical Sciences Institute, Wexford, Ireland, 7Molecular Rheumatology, Dublin, Ireland, 8Trinity College Dublin and University College Dublin, Dublin, Ireland, 9Trinity College, Dublin, Ireland, 10Tallaght University Hospital, Dublin, Ireland, 11Rheumatic Disease Associates, Warminster, PA, 12Janssen Research and Development, LLC, Spring House, PA, 13Janssen Research, Collegeville, PA, 14St. Vincent's University Hospital, Blackrock, Dublin, Ireland

    Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are common autoimmune diseases of unknown aetiology characterised by complex synovial pathology with a detrimental effect on the…
  • Abstract Number: 2141 • ACR Convergence 2022

    How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study

    Maria-Antonietta D'Agostino1, Philip G Conaghan2, Corine Gaillez3, Esperanza Naredo4, Peter mandl5, Philippe Carron6, Ladislav Šenolt7, Javier Eduardo Rosa8, Alejandra Lopez Rdz9, Punit Goyanka10, Braja Gopal Sahoo10, Weibin Bao11, Georg Schett12 and Maarten Boers13, 1Catholic University of Sacred Heart, Roma, Italy, 2University of Leeds, Leeds, United Kingdom, 3Novartis Pharma AG, Basel, Switzerland, 4Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, 5Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, 6Ghent University Hospital, Ghent, Belgium, 7Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 8Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, 10Novartis Healthcare Pvt Ltd, Hyderabad, India, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ, 12Universitätsklinikum Erlangen, Erlangen, Germany, 13Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands

    Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
  • Abstract Number: 0501 • ACR Convergence 2022

    Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia

    Roopa Madhu1, Kartik Bhamidipati1, Nghia Millard2, Michelle Curtis2, Ye Cui3, Youngmi Kim3, Ellen Gravallese4, Soumya Raychaudhuri1, Michael Brenner4, ilya Korsunsky1 and Kevin Wei5, 1Brigham and Women's Hospital, Boston, MA, 2Broad Institute, Boston, MA, 3Nanostring Technologies Inc., Seattle, WA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Chronic joint inflammation in rheumatoid arthritis (RA) arises from the interactions of many cell types. Single-cell transcriptomic profiling of RA joints has identified novel…
  • Abstract Number: 2166 • ACR Convergence 2022

    Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments

    Eric Schwender1, Dylan Hansen2, Wendy Stevens2, Laura Ross3, Nava Ferdowsi2, Susanna Proudman4, Jenny Walker5, Jo Sahhar6, Gene-Siew Ngian7, Lauren Host8, Gabor Major9, Mandana Nikpour10 and Kathleen Morrisroe2, 1Royal College of Surgeons, Dublin, Ireland, 2St Vincent's Hospital Melbourne, Melbourne, Australia, 3The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, 4Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, 5Royal Adelaide Hospital, Adelaide, Australia, 6Monash Health, Melbourne, Australia, 7Melbourne Health, Northcote, Australia, 8Fiona Stanley Hospital, London, United Kingdom, 9Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, 10The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: To characterise a cohort of Australian scleroderma patients with inflammatory arthritis including patient characteristics, autoantibody profile, therapy and impact on function and quality of…
  • Abstract Number: 0793 • ACR Convergence 2021

    Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan

    Shin-ya Kawashiri1, Tohru Michitsuji1, Yushiro Endo1, Ayako Nishino1, Toshimasa Shimizu1, Remi Sumiyoshi1, Tomohiro Koga1, Naoki Iwamoto1, Kunihiro Ichinose2 and Atsushi Kawakami1, 1Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan

    Background/Purpose: The concept of difficult-to-treat rheumatoid arthritis (D2T RA) has emerged as the greatest unmet need in recent years. We have investigated the clinical characteristics…
  • Abstract Number: 0800 • ACR Convergence 2021

    Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation

    Stefano Alivernini1, Simone Perniola2, Marco Gessi3, Maria Rita Gigante4, Clara Di Mario5, Luca Petricca4, Dario Bruno5, Laura Bui1, Annamaria Paglionico1, Valentina Varriano1, Maria Antonietta D'Agostino6, Barbara Tolusso1 and Elisa Gremese7, 1Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 2Fondazione Policlinico Universitario A. Gemelli IRCCS - University of Verona, Santeramo in Colle, Italy, 3Fondazione PoliclinicoUniversitario A. Gemelli IRCCS, Rome, Italy, 4Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 5Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, 6Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 7Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

    Background/Purpose: Sustained disease remission is the treatment goal for Rheumatoid Arthritis (RA) leading patients to be eligible to treatment tapering or discontinuation. However, disease flare…
  • Abstract Number: 0943 • ACR Convergence 2021

    Metabolomic Profiling of Synovial Tissue of Patients with Osteoarthritis

    Jessica Murillo Saich1, Roxana Coras2, Robert Meyer3 and Monica Guma4, 1University of California San Diego, La Jolla, CA, 2University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, 3San Diego VA Healthcare Service, La Jolla, CA, 4University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA

    Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated not simply by progressive degeneration of cartilage, but also by low-grade synovial inflammation (synovitis) that…
  • Abstract Number: 0945 • ACR Convergence 2021

    A Single-cell Atlas of Human Synovial Endothelial Cells in Inflammatory Arthritis

    Sam Edalat1, Reto Gerber2, Miranda Houtman1, Raphael Micheroli3, Kristina Buerki1, Nadja Izanc1, Blaz Burja4, Tadeja Kuret5, Snežna Sodin-Šemrl5, Adrian Ciurea3, Oliver Distler3, Caroline Ospelt1, Chantal Pauli6, Mark Robinson7 and Mojca Frank-Bertoncelj3, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich and Department of Molecular Life Sciences and SIB Swiss Institute of Bioinformatics, University of Zurich, Zurich, Switzerland, 3Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, 4Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich and Department of Rheumatology, University Medical Centre Ljubljana, Zurich, Switzerland, 5Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 6Department of Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7Department of Molecular Life Sciences and SIB Swiss Institute of Bioinformatics, University of Zurich, Zurich, Switzerland

    Background/Purpose: Dysregulated endothelial cell (EC) function and altered (lympho)angiogenesis crucially contribute to synovial pathology in inflammatory arthritis. Additionally, endothelium plays a key role in the…
  • Abstract Number: 0968 • ACR Convergence 2021

    Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells

    Anna Helena Jonsson1, Fan Zhang2, Emma Gomez-Rivas1, Gerald Watts1, Garett Dunlap3, Heather Faust1, Karishma Rupani1, Joseph Mears1, Deepak Rao1, Runci Wang4, Gregory Keras1, Nida Meednu5, Jonathan Coblyn1, Elena Massarotti1, Derrick Todd1, Andrew McDavid6, Jennifer Anolik5, Accelerating Medicines Partnership AMP: RA/SLE Network7, Kevin Wei1, Soumya Raychaudhuri1 and Michael Brenner8, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Harvard University, Somerville, MA, 4Brigham and Women’s Hospital, Boston, MA, 5University of Rochester Medical center, Rochester, NY, 6University of Rochester, Rochester, NY, 7NIH/FNIH, Bethesda, MD, 8Brigham and Women's Hospital, Harvard Medical School, Newton, MA

    Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology